Up-to-date List of Concor Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Concor Medical Research Studies

1 Not yet recruiting Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
Condition: Hypertension
Interventions: Drug: Bisoprolol/Amlodipine (Bisoprolol sub-group A);   Drug: Bisoprolol/Amlodipine (Bisoprolol sub-group B);   Drug: Bisoprolol/Amlodipine (Amlodipine sub-group A);   Drug: Bisoprolol/Amlodipine (Amlodipine sub-group B)
Outcome Measures: Mean reduction of systolic blood pressure (SBP) after 18 weeks of treatment from Baseline (latest SBP before study treatment);   Change from Baseline (latest diastolic blood pressure [DBP] before study treatment) in DBP after 18 weeks of treatment;   Percentage of subjects with controlled blood pressure under different dosages of after study treatment;   Change from Baseline (latest heart rate [HR] before study treatment) in HR after 18 weeks treatment;   Number of subjects with adverse events (AEs)
2 Recruiting Treating Clozapine-induced Sinustachycardia With Bisoprolol
Condition: Clozapine-induced Sinustachycardia
Interventions: Drug: Bisoprolol;   Drug: Placebo
Outcome Measures: Heart rate variability;   QTc, T-wave morphology and other ECG markers;   Hamilton-Anxiety scale;   Salivation rate;   Orthostatic blood pressure;   WHO-QoL;   Nocturnal Hypersalivation Rating Scale (NHRS).
3 Recruiting The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J)
Condition: Chronic Heart Failure
Interventions: Drug: Bisoprolol;   Drug: Carvedilol
Outcome Measures: Tolerability: The probability that administered maintenance dose reaches the maximum (bisoprolol 5 mg/day, carvedilol 20 mg/day);   Efficacy: New York Heart Association (NYHA) Functional Classification;   Efficacy: Left Ventricular Ejection Fraction (LVEF);   Efficacy: Left Ventricular End Diastolic Volume (LVEDV), Left Ventricular End Systolic Volume (LVESV);   Efficacy: Heart rate;   Efficacy: Plasma brain natriuretic peptide (BNP);   Safety: All deaths;   Safety: Deaths with cardiovascular causes;   Safety: Hospitalization for cardiovascular causes;   Safety: Exacerbation of heart failure, resulting in hospitalization, and/or intensification of treatment (increase in dose of any diuretics, vasodilators or cardiotonics, in comparison with the dose-setting period), or administration of new drugs.;   Safety: Deaths due to heart failure (pump-failure deaths, and deaths associated with exacerbation of heart failure);   Safety: Sudden deaths, including deaths due to arrhythmia;   Safety: Deaths with non-cardiovascular causes;   Safety: Adverse events;   Safety: Changes in clinical laboratory test results
4 Unknown  Comparison of Effect of cARvedilol Compared To bISoprolol on cenTral Pulse Pressure in Hypertension (ARTIST) Study
Condition: Hypertension
Interventions: Drug: carvedilol;   Drug: bisoprolol
Outcome Measures: Change in central pulse pressure (pulse pressure amplification);   Change in LV mass index Changes in LV diastolic functions (E/Em, left atrium volume) Changes in urinary albumin excretion, B-type natriuretic peptide (BNP), HOMA-IR, and oxidative stress (urinary 8-isoprostane). Change in ambulatory BP
5 Recruiting Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol
Conditions: Hypertension;   Metabolic Syndrome
Interventions: Drug: Atenolol;   Drug: Bisoprolol
Outcome Measures: central blood pressure;   peripheral resistance;   cardiac index;   pulse wave velocity
6 Not yet recruiting Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing
Condition: Heart Rate Control in ICD Patients With Heart Failure
Interventions: Drug: Ivabradine plus beta-blocker (bisoprolol);   Drug: betablocker titration
Outcome Measures: Right ventricular pacing percentage increase > 50% or cardiovascular death or Heart failure decompensation or Crossover due to worsening heart failure.;   Number of episodes of non-sustained and sustained ventricular tachycardia and ventricular fibrillation;   Number of ICD shock-delivery for ventricular fibrillation and sustained ventricular tachycardia;   Ejection fraction decrease < 5% from baseline value;   Left Ventricular End-Systolic Volume decrease <15% from baseline value;   Heart rate variability increase (> 10%) from baseline value;   reduction of at least one NYHA Class from baseline value;   Change in Minnesota Living Heart Failure Questionnaire scores (>5) from the baseline score.;   Right ventricular pacing percentage reduction (> 10%) from baseline value;   Composite endpoint: number of cardiovascular death and hospitalization due to worsening heart failure.;   Crossover rate due to worsening heart failure
7 Recruiting Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure
Conditions: Chronic Heart Failure;   Cachexia
Outcome Measures: Pharmacokinetic parameters of bisoprolol and ramipril;   Body composition;   Cachexia diagnosis;   Renal function
8 Recruiting Haemodynamics in Hypertension
Conditions: Primary Hypertension;   Secondary Hypertension;   Aortic Stenosis;   Renal Insufficiency
Interventions: Drug: Nitroglycerin 0.25 mg (single dose);   Drug: Salbutamol 400 µg (single dose);   Drug: L-arginine (10 min infusion);   Dietary Supplement: Liquorice (2 weeks, glycyrrhizin 290-370 mg daily);   Dietary Supplement: Small milk casein-derived polypeptides (yoghurt, 12 weeks daily);   Drug: Bisoprolol (5mg daily for 3 weeks)
Outcome Measures: Change in haemodynamic variables during the follow-up;   Haemodynamic response to head-up tilt and research drugs;   Haemodynamic response to bisoprolol or dietary supplements (liquorice, milk casein-derived polypeptides)
9 Not yet recruiting Atrial Fibrillation and By-pass Surgery
Condition: Patients With Coronary Artery Disease Scheduled for by Pass Surgery
Interventions: Drug: Amiodarone tab 200 mg x 3;   Drug: rosuvastatin 20 mg tab x1;   Drug: beta blockers Bisoprolol in adjusted dose
Outcome Measure: atrial fibrillation
10 Not yet recruiting Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation
Condition: Stable Angina
Interventions: Drug: Diltiazem treated group;   Drug: Bisoprolol treated group;   Drug: Candesartan treated group
Outcome Measures: Wall to lumen ratio of fundus vessel;   lipid parameter;   Serum markers of inflammation;   Change of nitrate need
11 Not yet recruiting Beta Blocker Therapy in Moderate to Severe COPD
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Biological: Carvedilol;   Biological: Bisoprolol;   Biological: Beclometasone/formoterol;   Biological: Tiotropium;   Biological: Beclometasone
Outcome Measures: Change in airway resistance at 5HZ (R5) using impulse oscillometry from baseline.;   Change in remaining impulse oscillometry measurements from baseline;   Change in spirometry measurements from baseline;   Change in echocardiogram parameters from baseline;   Change in vital signs from baseline;   Change in six minute walk test distance from baseline;   Change in St George's Respiratory Questionnaire score from baseline
12 Unknown  Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research
Conditions: Breast Cancer;   Heart Failure
Intervention: Drug: perindopril OR bisoprolol OR placebo
Outcome Measure: The primary objective is to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular (LV) remodeling among women with HER2+ early breast cancer.
13 Not yet recruiting Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes
Condition: Acute Coronary Syndromes
Interventions: Drug: Conservative Arm;   Procedure: Invasive Arm
Outcome Measures: Death;   non-fatal myocardial infarction;   Unplanned revascularisation;   Permanent Stroke;   Major bleeding;   Deterioration of renal function during hospital admission;   Angina symptoms (3 months; 1yr);   Stent thrombosis;   All cause mortality;   Hospital readmission for ACS/STEMI;   In-hospital major complications

These studies may lead to new treatments and are adding insight into Concor etiology and treatment.

A major focus of Concor research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Concor

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us

privacy policy